董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jason Rhodes | 男 | Director and Chairman of the Board | 55 | 未披露 | 未持股 | 2025-10-01 |
| Catherine Stehman Breen | 女 | Director | 62 | 11.26万美元 | 未持股 | 2025-10-01 |
| Dirk Kersten | 男 | Director | 50 | 未披露 | 未持股 | 2025-10-01 |
| Brian Posner | -- | Independent Director | -- | 未披露 | 未持股 | 2025-10-01 |
| Carlo Incerti | 男 | Director | -- | 未披露 | 未持股 | 2025-10-01 |
| Edward Hurwitz | 男 | Director | 61 | 未披露 | 未持股 | 2025-10-01 |
| David Lubner | 男 | Director | 60 | 未披露 | 未持股 | 2025-10-01 |
| John G. Cox | 男 | Chief Executive Officer,President and Director | 62 | 未披露 | 未持股 | 2025-10-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Erick Lucera | 男 | Chief Financial Officer and Treasurer | 57 | 未披露 | 未持股 | 2025-10-01 |
| Douglas Kerr | 男 | Chief Medical Officer | 58 | 未披露 | 未持股 | 2025-10-01 |
| Oxana Beskrovnaya | 女 | Chief Scientific Officer | 64 | 未披露 | 未持股 | 2025-10-01 |
| Johanna Friedl Naderer | 女 | Chief Commercial Officer | -- | 未披露 | 未持股 | 2025-10-01 |
| John G. Cox | 男 | Chief Executive Officer,President and Director | 62 | 未披露 | 未持股 | 2025-10-01 |
董事简历
中英对照 | 中文 | 英文- Jason Rhodes
-
Jason Rhodes自2017年12月起担任公司董事，自2018年11月起担任董事会主席。罗兹先生还于2017年12月至2018年11月担任我们的创始总裁兼首席执行官。Rhodes先生自2014年以来一直担任Atlas Venture的合伙人。从2010年到2014年，罗兹受聘于生物技术公司Epizyme，Inc.，最近担任该公司总裁兼首席财务官。罗兹先生是ReplimuneGroup，Inc.，Generation BioCo.和多家私人公司的董事会成员，曾于2016年至2019年担任Bicycle Therapeutics，Inc.的董事。Rhodes先生在耶鲁大学（Yale University）获得历史学学士学位，在宾夕法尼亚大学沃顿商学院（Wharton School of Pennsylvania）获得工商管理硕士学位。
Jason Rhodes has been a member of our Board since April 2016. Since 2014 Mr. Rhodes has been a partner at Atlas Ventures, a venture capital firm. Mr. Rhodes also served as the founding President and Chief Executive Officer of Dyne Therapeutics, Inc. from December 2017 to November 2018. From 2010 to 2014 Mr. Rhodes was at Epizyme, Inc., a biotechnology company, where he most recently served as President and Chief Financial Officer. Prior to that, he led business development at Alnylam Pharmaceuticals, Inc. from 2007 to 2010. Mr. Rhodes currently serves as the chairman of the board of directors of Generation Bio Co., the chairman of the board of directors of Dyne Therapeutics, Inc., and as a member of the board of directors of Replimune Group, Inc. and several private companies, and previously served as a director at Bicycle Therapeutics, Inc. from 2016 to 2020. Mr. Rhodes earned a B.A. in history from Yale University and an M.B.A. from the Wharton School of the University of Pennsylvania. - Jason Rhodes自2017年12月起担任公司董事，自2018年11月起担任董事会主席。罗兹先生还于2017年12月至2018年11月担任我们的创始总裁兼首席执行官。Rhodes先生自2014年以来一直担任Atlas Venture的合伙人。从2010年到2014年，罗兹受聘于生物技术公司Epizyme，Inc.，最近担任该公司总裁兼首席财务官。罗兹先生是ReplimuneGroup，Inc.，Generation BioCo.和多家私人公司的董事会成员，曾于2016年至2019年担任Bicycle Therapeutics，Inc.的董事。Rhodes先生在耶鲁大学（Yale University）获得历史学学士学位，在宾夕法尼亚大学沃顿商学院（Wharton School of Pennsylvania）获得工商管理硕士学位。
- Jason Rhodes has been a member of our Board since April 2016. Since 2014 Mr. Rhodes has been a partner at Atlas Ventures, a venture capital firm. Mr. Rhodes also served as the founding President and Chief Executive Officer of Dyne Therapeutics, Inc. from December 2017 to November 2018. From 2010 to 2014 Mr. Rhodes was at Epizyme, Inc., a biotechnology company, where he most recently served as President and Chief Financial Officer. Prior to that, he led business development at Alnylam Pharmaceuticals, Inc. from 2007 to 2010. Mr. Rhodes currently serves as the chairman of the board of directors of Generation Bio Co., the chairman of the board of directors of Dyne Therapeutics, Inc., and as a member of the board of directors of Replimune Group, Inc. and several private companies, and previously served as a director at Bicycle Therapeutics, Inc. from 2016 to 2020. Mr. Rhodes earned a B.A. in history from Yale University and an M.B.A. from the Wharton School of the University of Pennsylvania.
- Catherine Stehman Breen
-
Catherine Stehman Breen自2019年6月起担任公司董事。Stehman-Breen博士自2019年7月起担任生物技术公司Obsidian Therapeutics，Inc.的首席开发官。此前，她曾担任Atlas Venture的常驻企业家，并于2018年3月至2019年7月担任我们公司的首席医疗官，并于2018年4月至2019年7月担任生物技术公司Disarm Therapeutics，Inc.的首席医疗官。Stehman-Breen博士还于2017年3月至2017年12月担任SareptaTherapeutics，Inc.首席医疗官。在此之前，Stehman-Breen博士于2015年1月至2017年3月担任生物技术公司再生元制药公司临床开发和监管事务Vice President，最初担任疼痛治疗领域主管，随后担任临床项目管理和运营主管。Stehman-Breen博士担任Generation BioCo.和Tenaya Therapeutics，Inc.的董事会成员。Stehman-Breen博士在科尔比学院（Colby College）获得生物学和心理学学士学位。她在华盛顿大学（University of Washington）获得流行病学学位，在那里她还进行了住院医师和奖学金培训，并在芝加哥大学（University of Chicago）获得医学博士学位。
Catherine Stehman Breen has served as a member of our board of directors since June 2020. Beginning in December 2020 Dr. Stehman-Breen has served as the Chief Executive Officer and a member of the board of directors of Chroma Medicine, a private biotechnology company. From July 2019 to December 2020 Dr. Stehman-Breen served as Chief Development Officer of Obsidian Therapeutics, a private biotechnology company. Since March 2018 she has served as an entrepreneur-in-residence at Atlas Ventures, a venture capital firm. Dr. Stehman-Brown serves as a director of Generation Bio, a public biotechnology company. Dr. Stehman-Breen also serves a member of the board of directors of Dyne Therapeutics, a public biotechnology company. She also previously served as Dyne’s Chief Medical Officer from March 2018 to July 2019. From April 2018 to July 2019 Dr. Stehman-Breen served as Chief Medical Officer Disarm Therapeutics, a private biotechnology company. From March 2017 to December 2017 she served as Chief Medical Officer of Sarepta Therapeutics, a public biopharmaceutical company. Before that, she served as Vice President, Clinical Development and Regulatory Affairs at Regeneron Pharmaceuticals, a public biotechnology company, from January 2015 to March 2017. From 2003 to 2015 she held senior leadership roles at Amgen including Vice President, Global Development, leading the neuroscience, nephrology and bone therapeutic areas. Dr. Stehman-Breen earned a B.A. in biology and psychology from Colby College, an M.S. in epidemiology from the University of Washington, where she also completed her residency and fellowship training, and an M.D. from the University of Chicago in 1990. Dr. Stehman-Breen spent six years as a faculty member in the Division of Nephrology at the University of Washington. - Catherine Stehman Breen自2019年6月起担任公司董事。Stehman-Breen博士自2019年7月起担任生物技术公司Obsidian Therapeutics，Inc.的首席开发官。此前，她曾担任Atlas Venture的常驻企业家，并于2018年3月至2019年7月担任我们公司的首席医疗官，并于2018年4月至2019年7月担任生物技术公司Disarm Therapeutics，Inc.的首席医疗官。Stehman-Breen博士还于2017年3月至2017年12月担任SareptaTherapeutics，Inc.首席医疗官。在此之前，Stehman-Breen博士于2015年1月至2017年3月担任生物技术公司再生元制药公司临床开发和监管事务Vice President，最初担任疼痛治疗领域主管，随后担任临床项目管理和运营主管。Stehman-Breen博士担任Generation BioCo.和Tenaya Therapeutics，Inc.的董事会成员。Stehman-Breen博士在科尔比学院（Colby College）获得生物学和心理学学士学位。她在华盛顿大学（University of Washington）获得流行病学学位，在那里她还进行了住院医师和奖学金培训，并在芝加哥大学（University of Chicago）获得医学博士学位。
- Catherine Stehman Breen has served as a member of our board of directors since June 2020. Beginning in December 2020 Dr. Stehman-Breen has served as the Chief Executive Officer and a member of the board of directors of Chroma Medicine, a private biotechnology company. From July 2019 to December 2020 Dr. Stehman-Breen served as Chief Development Officer of Obsidian Therapeutics, a private biotechnology company. Since March 2018 she has served as an entrepreneur-in-residence at Atlas Ventures, a venture capital firm. Dr. Stehman-Brown serves as a director of Generation Bio, a public biotechnology company. Dr. Stehman-Breen also serves a member of the board of directors of Dyne Therapeutics, a public biotechnology company. She also previously served as Dyne’s Chief Medical Officer from March 2018 to July 2019. From April 2018 to July 2019 Dr. Stehman-Breen served as Chief Medical Officer Disarm Therapeutics, a private biotechnology company. From March 2017 to December 2017 she served as Chief Medical Officer of Sarepta Therapeutics, a public biopharmaceutical company. Before that, she served as Vice President, Clinical Development and Regulatory Affairs at Regeneron Pharmaceuticals, a public biotechnology company, from January 2015 to March 2017. From 2003 to 2015 she held senior leadership roles at Amgen including Vice President, Global Development, leading the neuroscience, nephrology and bone therapeutic areas. Dr. Stehman-Breen earned a B.A. in biology and psychology from Colby College, an M.S. in epidemiology from the University of Washington, where she also completed her residency and fellowship training, and an M.D. from the University of Chicago in 1990. Dr. Stehman-Breen spent six years as a faculty member in the Division of Nephrology at the University of Washington.
- Dirk Kersten
-
Dirk Kersten自2018年11月起担任公司董事。Kersten先生自2018年10月起担任Forbion的普通合伙人。Kersten先生是一名受过培训的物理学家，曾于2014年5月至2018年8月担任Inkef Capital的董事总经理，负责所有梦百合投资活动。在加入Inkef Capital之前，Kersten先生于2006年至2014年担任Gilde梦百合Partners的合伙人，包括领导其美国业务的三年时间。Kersten先生曾担任多家私人生命科学公司的董事，包括Ascendis Pharma，Profibrix，Lanthio Pharma，NightBalance，Audion Therapeutics，GTX和Vicentra。Kersten先生在荷兰格罗宁根大学（University of Groningen）获得物理学硕士学位。
Dirk Kersten has served as a director of our company since November 2018. Mr. Kersten has served as a general partner at Forbion since October 2018. Mr. Kersten is a physicist by training and previously was a managing director at INKEF Capital from May 2014 to August 2018 where he was responsible for all healthcare investment activities. Prior to joining INKEF Capital, Mr. Kersten was a partner at Gilde Healthcare Partners from 2006 to 2014 including a period of three years when he led its U.S. operations. Mr. Kersten served as a director of a number of private life science companies, including Ascendis Pharma, Profibrix, Lanthio Pharma, Nightbalance, Audion Therapeutics, GTX and Vicentra. Mr. Kersten received his M.S. in physics from the University of Groningen in the Netherlands. - Dirk Kersten自2018年11月起担任公司董事。Kersten先生自2018年10月起担任Forbion的普通合伙人。Kersten先生是一名受过培训的物理学家，曾于2014年5月至2018年8月担任Inkef Capital的董事总经理，负责所有梦百合投资活动。在加入Inkef Capital之前，Kersten先生于2006年至2014年担任Gilde梦百合Partners的合伙人，包括领导其美国业务的三年时间。Kersten先生曾担任多家私人生命科学公司的董事，包括Ascendis Pharma，Profibrix，Lanthio Pharma，NightBalance，Audion Therapeutics，GTX和Vicentra。Kersten先生在荷兰格罗宁根大学（University of Groningen）获得物理学硕士学位。
- Dirk Kersten has served as a director of our company since November 2018. Mr. Kersten has served as a general partner at Forbion since October 2018. Mr. Kersten is a physicist by training and previously was a managing director at INKEF Capital from May 2014 to August 2018 where he was responsible for all healthcare investment activities. Prior to joining INKEF Capital, Mr. Kersten was a partner at Gilde Healthcare Partners from 2006 to 2014 including a period of three years when he led its U.S. operations. Mr. Kersten served as a director of a number of private life science companies, including Ascendis Pharma, Profibrix, Lanthio Pharma, Nightbalance, Audion Therapeutics, GTX and Vicentra. Mr. Kersten received his M.S. in physics from the University of Groningen in the Netherlands.
- Brian Posner
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Carlo Incerti
-
Carlo Incerti，自2022年3月起担任Dyne Therapeutics，Inc.公司董事。Incerti博士自2019年1月起担任Forbion的运营合伙人。此前，他于2011年5月至2018年12月在医疗保健旗下公司赛诺菲 Genzyme担任高级副总裁、首席医疗官兼全球医疗事务主管。在2011年赛诺菲收购生物技术公司健赞之前，Incerti博士于2010年至2011年在Genzyme担任全球市场准入高级副总裁，并于1993年至2010年在Genzyme位于荷兰的欧洲总部担任多个职位。Incerti博士担任Azafaros B.V.、Synox Therapeutics Ltd.和Numab Therapeutics AG.的董事会成员，此前曾于2016年至2020年担任MolMed SpA、2020年至2023年担任Erydel SpA、2020年至2023年担任Inversago Pharma，Inc.以及2020年10月至2024年6月担任Vectory B.V.的董事。Incerti博士也是国际罕见病研究联盟的创始成员。他在意大利的莫德纳大学和雷焦艾米利亚大学获得医学学位。
Carlo Incerti,has served as a director of Dyne Therapeutics, Inc. company since March 2022. Dr. Incerti has served as an operating partner at Forbion since January 2019. Previously, he served as Senior Vice President, Chief Medical Officer and Head of Global Medical Affairs at Sanofi Genzyme, a healthcare company, from May 2011 to December 2018. Prior to the acquisition of Genzyme Corporation, a biotechnology company, by Sanofi in 2011, Dr. Incerti served as Senior Vice President of Global Market Access at Genzyme from 2010 to 2011 and held a number of positions at Genzyme in their European headquarters in the Netherlands from 1993 to 2010. Dr. Incerti serves as a member of the board of directors at Azafaros B.V., Synox Therapeutics Ltd. and Numab Therapeutics AG., and previously served as a director at MolMed SpA from 2016 to 2020, EryDel SpA from 2020 to 2023, Inversago Pharma, Inc. from 2020 to 2023, and Vectory B.V. from October 2020 to June 2024. Dr. Incerti is also a founding member of the International Rare Diseases Research Consortium. He received his medical degree from the University of Modena and Reggio Emilia in Italy. - Carlo Incerti，自2022年3月起担任Dyne Therapeutics，Inc.公司董事。Incerti博士自2019年1月起担任Forbion的运营合伙人。此前，他于2011年5月至2018年12月在医疗保健旗下公司赛诺菲 Genzyme担任高级副总裁、首席医疗官兼全球医疗事务主管。在2011年赛诺菲收购生物技术公司健赞之前，Incerti博士于2010年至2011年在Genzyme担任全球市场准入高级副总裁，并于1993年至2010年在Genzyme位于荷兰的欧洲总部担任多个职位。Incerti博士担任Azafaros B.V.、Synox Therapeutics Ltd.和Numab Therapeutics AG.的董事会成员，此前曾于2016年至2020年担任MolMed SpA、2020年至2023年担任Erydel SpA、2020年至2023年担任Inversago Pharma，Inc.以及2020年10月至2024年6月担任Vectory B.V.的董事。Incerti博士也是国际罕见病研究联盟的创始成员。他在意大利的莫德纳大学和雷焦艾米利亚大学获得医学学位。
- Carlo Incerti,has served as a director of Dyne Therapeutics, Inc. company since March 2022. Dr. Incerti has served as an operating partner at Forbion since January 2019. Previously, he served as Senior Vice President, Chief Medical Officer and Head of Global Medical Affairs at Sanofi Genzyme, a healthcare company, from May 2011 to December 2018. Prior to the acquisition of Genzyme Corporation, a biotechnology company, by Sanofi in 2011, Dr. Incerti served as Senior Vice President of Global Market Access at Genzyme from 2010 to 2011 and held a number of positions at Genzyme in their European headquarters in the Netherlands from 1993 to 2010. Dr. Incerti serves as a member of the board of directors at Azafaros B.V., Synox Therapeutics Ltd. and Numab Therapeutics AG., and previously served as a director at MolMed SpA from 2016 to 2020, EryDel SpA from 2020 to 2023, Inversago Pharma, Inc. from 2020 to 2023, and Vectory B.V. from October 2020 to June 2024. Dr. Incerti is also a founding member of the International Rare Diseases Research Consortium. He received his medical degree from the University of Modena and Reggio Emilia in Italy.
- Edward Hurwitz
-
Edward Hurwitz，他一直担任公司董事（2018年11月以来）。他曾担任MPM Capital的董事总经理（2017年1月以来），以及Precision BioVentures的董事总经理（2013年创立公司以来）。在加入MPM Capital之前，他从2002年到2014年12月担任Alta Partners的董事。在加入Alta Partners之前，Hurwitz先生从1997年到2002年担任Affymetrix的高级副总裁兼首席财务官。在任职Affymetrix之前，他是Robertson Stephens & Company和Smith Barney Shearson的生物技术研究分析师，也是Cooley Godward LLP的律师。2008年至2014年，他曾担任上市公司Sunesis Pharmaceuticals的董事；2006年至2014年，他曾担任上市公司Cara Therapeutics的董事。Hurwitz先生担任MacroGenics， Inc.和Applied Genetic Technologies Corporation以及几家私人公司的董事会成员。他持有California大学伯克利分校的法学博士和工商管理硕士学位，以及Cornell大学的分子生物学学士学位。
Edward Hurwitz has served as a director of company since November 2018. Mr. Hurwitz has served as a Managing Director at MPM Capital since January 2017 and as Managing Director of Precision BioVentures since he founded the firm in 2013. Prior to joining MPM Capital, Mr. Hurwitz was a Director at Alta Partners from 2002 through December 2014. Prior to joining Alta Partners, Mr. Hurwitz served as Senior Vice President and CFO of Affymetrix from 1997 to 2002. Prior to his service at Affymetrix, Mr. Hurwitz was a biotechnology research analyst for Robertson Stephens&Company and Smith Barney Shearson and a lawyer at Cooley Godward LLP. Mr. Hurwitz previously served as a director of Sunesis Pharmaceuticals, Inc., a publicly held company, from 2008 to 2014 and as a director of Cara Therapeutics, Inc., a publicly held company, from 2006 to 2014. Mr. Hurwitz serves as a member of the board of directors of MacroGenics, Inc. and Applied Genetic Technologies Corporation and several private companies. Mr. Hurwitz earned his J.D. and M.B.A. degrees from the University of California, Berkeley, and his B.A. in molecular biology from Cornell University. - Edward Hurwitz，他一直担任公司董事（2018年11月以来）。他曾担任MPM Capital的董事总经理（2017年1月以来），以及Precision BioVentures的董事总经理（2013年创立公司以来）。在加入MPM Capital之前，他从2002年到2014年12月担任Alta Partners的董事。在加入Alta Partners之前，Hurwitz先生从1997年到2002年担任Affymetrix的高级副总裁兼首席财务官。在任职Affymetrix之前，他是Robertson Stephens & Company和Smith Barney Shearson的生物技术研究分析师，也是Cooley Godward LLP的律师。2008年至2014年，他曾担任上市公司Sunesis Pharmaceuticals的董事；2006年至2014年，他曾担任上市公司Cara Therapeutics的董事。Hurwitz先生担任MacroGenics， Inc.和Applied Genetic Technologies Corporation以及几家私人公司的董事会成员。他持有California大学伯克利分校的法学博士和工商管理硕士学位，以及Cornell大学的分子生物学学士学位。
- Edward Hurwitz has served as a director of company since November 2018. Mr. Hurwitz has served as a Managing Director at MPM Capital since January 2017 and as Managing Director of Precision BioVentures since he founded the firm in 2013. Prior to joining MPM Capital, Mr. Hurwitz was a Director at Alta Partners from 2002 through December 2014. Prior to joining Alta Partners, Mr. Hurwitz served as Senior Vice President and CFO of Affymetrix from 1997 to 2002. Prior to his service at Affymetrix, Mr. Hurwitz was a biotechnology research analyst for Robertson Stephens&Company and Smith Barney Shearson and a lawyer at Cooley Godward LLP. Mr. Hurwitz previously served as a director of Sunesis Pharmaceuticals, Inc., a publicly held company, from 2008 to 2014 and as a director of Cara Therapeutics, Inc., a publicly held company, from 2006 to 2014. Mr. Hurwitz serves as a member of the board of directors of MacroGenics, Inc. and Applied Genetic Technologies Corporation and several private companies. Mr. Hurwitz earned his J.D. and M.B.A. degrees from the University of California, Berkeley, and his B.A. in molecular biology from Cornell University.
- David Lubner
-
David Lubner，2010年10月起，他担任Arcellx, Inc.高级副总裁和首席财务官，2006年公司成立至2010年10月，担任兼职高级副总裁和首席运营官。2006至2010年10月，他还担任风险投资公司Mediphase Venture Partners的首席财务官。1999至2005年被IMS Health收购，他担任PharMetrics, Inc.的副总裁和首席财务官，该公司是制药和医学索赔数据信息公司。加入PharMetrics之前，1996至1999年，他担任生物制药公司ProScript, Inc.的副总裁和首席财务官。他是美国注册会计师协会（American Institute of CPAs）的成员。他在东北大学（Northeastern University）获得工商管理学士学位，在本特利大学（Bentley University）获得税收硕士学位。
David Lubner,has served as a member of Cargo Therapeutics, Inc. board of directors since July 2023. From January 2016 until June 2020, Mr. Lubner served as Executive Vice President and Chief Financial Officer of Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, acquired by UCB S.A. in April 2020. Prior to joining Ra Pharmaceuticals, Mr. Lubner served as Chief Financial Officer of Tetraphase Pharmaceuticals, Inc., a biotechnology company, from 2006 through 2016, and as Chief Financial Officer of PharMetrics Inc., a patient-based pharmacy and medical claims data informatics company, from 1999 until 2006. Prior to joining PharMetrics, Mr. Lubner served as Vice President and Chief Financial Officer of ProScript, Inc. from 1996 to 1999. Mr. Lubner currently serves on the board of directors of a number of publicly traded biotechnology companies, including Arcellx, Inc., Dyne Therapeutics, Inc., POINT Biopharma, Inc. and Vor Biopharma, Inc. He was previously a member of the board of directors of Gemini Therapeutics, Inc., which merged with Disc Medicine, Inc. in December 2022, Nightstar Therapeutics plc, which was acquired by Biogen Inc. in June 2019, and Therapeutics Acquisition Corp., a blank check company focused on the healthcare industry, sponsored by RA Capital, Boston, MA. Mr. Lubner is a Certified Public Accountant in the Commonwealth of Massachusetts. Mr. Lubner received his B.S. in Business Administration from Northeastern University and M.S. in Taxation from Bentley University. - David Lubner，2010年10月起，他担任Arcellx, Inc.高级副总裁和首席财务官，2006年公司成立至2010年10月，担任兼职高级副总裁和首席运营官。2006至2010年10月，他还担任风险投资公司Mediphase Venture Partners的首席财务官。1999至2005年被IMS Health收购，他担任PharMetrics, Inc.的副总裁和首席财务官，该公司是制药和医学索赔数据信息公司。加入PharMetrics之前，1996至1999年，他担任生物制药公司ProScript, Inc.的副总裁和首席财务官。他是美国注册会计师协会（American Institute of CPAs）的成员。他在东北大学（Northeastern University）获得工商管理学士学位，在本特利大学（Bentley University）获得税收硕士学位。
- David Lubner,has served as a member of Cargo Therapeutics, Inc. board of directors since July 2023. From January 2016 until June 2020, Mr. Lubner served as Executive Vice President and Chief Financial Officer of Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, acquired by UCB S.A. in April 2020. Prior to joining Ra Pharmaceuticals, Mr. Lubner served as Chief Financial Officer of Tetraphase Pharmaceuticals, Inc., a biotechnology company, from 2006 through 2016, and as Chief Financial Officer of PharMetrics Inc., a patient-based pharmacy and medical claims data informatics company, from 1999 until 2006. Prior to joining PharMetrics, Mr. Lubner served as Vice President and Chief Financial Officer of ProScript, Inc. from 1996 to 1999. Mr. Lubner currently serves on the board of directors of a number of publicly traded biotechnology companies, including Arcellx, Inc., Dyne Therapeutics, Inc., POINT Biopharma, Inc. and Vor Biopharma, Inc. He was previously a member of the board of directors of Gemini Therapeutics, Inc., which merged with Disc Medicine, Inc. in December 2022, Nightstar Therapeutics plc, which was acquired by Biogen Inc. in June 2019, and Therapeutics Acquisition Corp., a blank check company focused on the healthcare industry, sponsored by RA Capital, Boston, MA. Mr. Lubner is a Certified Public Accountant in the Commonwealth of Massachusetts. Mr. Lubner received his B.S. in Business Administration from Northeastern University and M.S. in Taxation from Bentley University.
- John G. Cox
-
John G. Cox从2013年11月开始担任Repligen董事。Cox先生目前是Biogen Idec执行副总，负责医药运营&科技，这个职位他从2010年6月开始担任。Cox先生也担任Technical Operations高级副总，Global Manufacturing高级副总，Biogen Idec在北加州的Research Triangle Park的业务的生产负责和总经理，以及生产负责人。Cox先生在2003年加入Biogen Idec，作为生产科学负责人。在加入Biogen Idec之前，在2000年到2003年之间，Cox先生担任Diosynth许多高级运营岗位，在那他任职于科技转化，验证和纯化。在那之前，在1993年到2000年之间，Cox先生在Wyeth LLC关注相同的领域。Cox先生获得California State University的细胞生物学士学位和the University of Michigan的金融类工商管理研究生学位。
John G. Cox has served as a director of Repligen since November 2013. Mr. Cox is currently the CEO of Bioverativ Inc. Previously, he was the Executive Vice President of Pharmaceutical Operations & Technology at Biogen Inc., a position he held for six years. Mr. Cox has also served as Senior Vice President of Technical Operations, Senior Vice President of Global Manufacturing, Vice President of Manufacturing & General Manager of Biogen's operations in Research Triangle Park, North Carolina, and Director of Manufacturing. Mr. Cox joined Biogen in 2003 as Director of Manufacturing Sciences. Before joining Biogen from 2000 to 2003 Mr. Cox held a number of senior operational roles at Diosynth where he worked in technology transfer, validation and purification. Prior to that, Mr. Cox focused on the same areas at Wyeth LLC from 1993 to 2000. Mr. Cox received a B.S. in cell biology from California State University and an M.A. in Business Administration in Finance degree from the University of Michigan. - John G. Cox从2013年11月开始担任Repligen董事。Cox先生目前是Biogen Idec执行副总，负责医药运营&科技，这个职位他从2010年6月开始担任。Cox先生也担任Technical Operations高级副总，Global Manufacturing高级副总，Biogen Idec在北加州的Research Triangle Park的业务的生产负责和总经理，以及生产负责人。Cox先生在2003年加入Biogen Idec，作为生产科学负责人。在加入Biogen Idec之前，在2000年到2003年之间，Cox先生担任Diosynth许多高级运营岗位，在那他任职于科技转化，验证和纯化。在那之前，在1993年到2000年之间，Cox先生在Wyeth LLC关注相同的领域。Cox先生获得California State University的细胞生物学士学位和the University of Michigan的金融类工商管理研究生学位。
- John G. Cox has served as a director of Repligen since November 2013. Mr. Cox is currently the CEO of Bioverativ Inc. Previously, he was the Executive Vice President of Pharmaceutical Operations & Technology at Biogen Inc., a position he held for six years. Mr. Cox has also served as Senior Vice President of Technical Operations, Senior Vice President of Global Manufacturing, Vice President of Manufacturing & General Manager of Biogen's operations in Research Triangle Park, North Carolina, and Director of Manufacturing. Mr. Cox joined Biogen in 2003 as Director of Manufacturing Sciences. Before joining Biogen from 2000 to 2003 Mr. Cox held a number of senior operational roles at Diosynth where he worked in technology transfer, validation and purification. Prior to that, Mr. Cox focused on the same areas at Wyeth LLC from 1993 to 2000. Mr. Cox received a B.S. in cell biology from California State University and an M.A. in Business Administration in Finance degree from the University of Michigan.
高管简历
中英对照 | 中文 | 英文- Erick Lucera
Erick Lucera于2017年8月加入Beyond Air, Inc.董事会。他被任命为AVEO Oncology（Nasdaq：AVEO）的首席财务官，AVEO Oncology是一家在纳斯达克上市的生物制药公司，2020年专注于满足肿瘤和其他未满足的医疗需求的靶向药物。2016年至2019年，Lucera先生担任Valeritas Holdings, Inc.（一家在美国纳斯达克上市的商业公司，开发糖尿病新技术）的首席财务官。Lucera先生于2015年至2016年担任Viventia Bio首席财务官、财务主管兼秘书。2012年至2015年，他在兽用生物制药公司Aratana Therapeutics担任企业发展副总裁。在Aratana任职期间，他通过一系列收购和通过五次公开和非公开发行融资近2.5亿美元的授权交易，帮助扩大了公司的产品线。在担任医疗保健公司高管之前，Lucera先生在投资管理领域度过了超过15年，曾担任Eaton Vance公司的医疗保健分析师、Intrepid Capital的铁人三项生命科学基金的投资组合经理以及Independence Investments的医疗保健研究团队负责人。自2021年10月起，他担任Bone Biologics的董事会成员，Bone Biologics是一家在纳斯达克上市的生物制剂公司。他拥有哈佛大学公共卫生证书、波士顿学院量化金融硕士学位、印第安纳大学布卢明顿分校MBA学位和特拉华大学会计学学士学位。Lucera先生已获得CFA、CMA和注册会计师称号。
Erick Lucera,joined Board of Directors in August 2017 and serves on audit committee, compensation committee and nominating committee. DYNE THERAPEUTICS He previously served as Executive Vice President and Chief Financial Officer of Editas Medicine, Inc., a leading gene editing company focused on developing CRISPR medicines for people with serious diseases, from May 2023 to March 2025. Mr. Lucera previously served as Chief Financial Officer of AVEO Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on targeted medicines for oncology and other unmet medical needs, from January 2020 until March 2023, following its acquisition by LG Chem, Ltd. Since April 2023, Mr. Lucera has served on the board of directors of SAB Biotherapeutics, Inc., a public clinical-stage biopharmaceutical company. Mr. Lucera was the Chief Financial Officer of Valeritas Holdings, Inc., a U.S. Nasdaq traded commercial stage company developing new technology for diabetes, from 2016 to 2019. Mr. Lucera served as Chief Financial Officer, Treasurer and Secretary of Viventia Bio from 2015 to 2016. From 2012 to 2015, he was Vice President, Corporate Development at Aratana Therapeutics, a veterinary biopharmaceutical company. While at Aratana, he helped grow the company's product pipeline through a series of acquisitions and in licensing transactions financed through five public and private offerings of nearly $250 million. Before his career as a healthcare company executive, Mr. Lucera spent over 15 years in investment management as a healthcare analyst at Eaton Vance, the portfolio manager of the Triathlon Life Sciences Fund at Intrepid Capital and as head of the healthcare research team at Independence Investments. He has served on the board of directors of Bone Biologics, a Nasdaq traded orthobiologics company, since October 2021. He holds a CPH from Harvard University, an MS in quantitative finance from Boston College, an MBA from Indiana University Bloomington, and a BS in accounting from the University of Delaware. Mr. Lucera has obtained CFA, CMA, and CPA designations.- Erick Lucera于2017年8月加入Beyond Air, Inc.董事会。他被任命为AVEO Oncology（Nasdaq：AVEO）的首席财务官，AVEO Oncology是一家在纳斯达克上市的生物制药公司，2020年专注于满足肿瘤和其他未满足的医疗需求的靶向药物。2016年至2019年，Lucera先生担任Valeritas Holdings, Inc.（一家在美国纳斯达克上市的商业公司，开发糖尿病新技术）的首席财务官。Lucera先生于2015年至2016年担任Viventia Bio首席财务官、财务主管兼秘书。2012年至2015年，他在兽用生物制药公司Aratana Therapeutics担任企业发展副总裁。在Aratana任职期间，他通过一系列收购和通过五次公开和非公开发行融资近2.5亿美元的授权交易，帮助扩大了公司的产品线。在担任医疗保健公司高管之前，Lucera先生在投资管理领域度过了超过15年，曾担任Eaton Vance公司的医疗保健分析师、Intrepid Capital的铁人三项生命科学基金的投资组合经理以及Independence Investments的医疗保健研究团队负责人。自2021年10月起，他担任Bone Biologics的董事会成员，Bone Biologics是一家在纳斯达克上市的生物制剂公司。他拥有哈佛大学公共卫生证书、波士顿学院量化金融硕士学位、印第安纳大学布卢明顿分校MBA学位和特拉华大学会计学学士学位。Lucera先生已获得CFA、CMA和注册会计师称号。
- Erick Lucera,joined Board of Directors in August 2017 and serves on audit committee, compensation committee and nominating committee. DYNE THERAPEUTICS He previously served as Executive Vice President and Chief Financial Officer of Editas Medicine, Inc., a leading gene editing company focused on developing CRISPR medicines for people with serious diseases, from May 2023 to March 2025. Mr. Lucera previously served as Chief Financial Officer of AVEO Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on targeted medicines for oncology and other unmet medical needs, from January 2020 until March 2023, following its acquisition by LG Chem, Ltd. Since April 2023, Mr. Lucera has served on the board of directors of SAB Biotherapeutics, Inc., a public clinical-stage biopharmaceutical company. Mr. Lucera was the Chief Financial Officer of Valeritas Holdings, Inc., a U.S. Nasdaq traded commercial stage company developing new technology for diabetes, from 2016 to 2019. Mr. Lucera served as Chief Financial Officer, Treasurer and Secretary of Viventia Bio from 2015 to 2016. From 2012 to 2015, he was Vice President, Corporate Development at Aratana Therapeutics, a veterinary biopharmaceutical company. While at Aratana, he helped grow the company's product pipeline through a series of acquisitions and in licensing transactions financed through five public and private offerings of nearly $250 million. Before his career as a healthcare company executive, Mr. Lucera spent over 15 years in investment management as a healthcare analyst at Eaton Vance, the portfolio manager of the Triathlon Life Sciences Fund at Intrepid Capital and as head of the healthcare research team at Independence Investments. He has served on the board of directors of Bone Biologics, a Nasdaq traded orthobiologics company, since October 2021. He holds a CPH from Harvard University, an MS in quantitative finance from Boston College, an MBA from Indiana University Bloomington, and a BS in accounting from the University of Delaware. Mr. Lucera has obtained CFA, CMA, and CPA designations.
- Douglas Kerr
Douglas Kerr自2019年5月起担任我们的首席开发官。此前，克尔博士于2017年8月至2019年5月担任研究与开发首席科学官兼执行Vice President。在加入我们之前，Kerr博士于2015年10月至2017年8月担任生物制药公司Shire plc神经病学全球开发团队负责人兼Vice President。Kerr博士在普林斯顿大学（Princeton University）获得生物化学学士学位，并在东北大学（Northeastern University）获得工商管理硕士学位，专业是创业和金融，在杰斐逊医学院（Jefferson Medical College）获得医学博士学位，并获得生物化学和分子生物学博士学位。
Douglas Kerr has served as our chief development officer since May 2019. Previously, Dr. Kerr served as our chief scientific officer and executive vice president of research and development from August 2017 to May 2019. Prior to joining us, Dr. Kerr served as global development team lead and vice president for neurology at Shire plc, a biopharmaceutical company, from October 2015 to August 2017. Dr. Kerr earned a B.A. degree in biochemistry from Princeton University and, an M.B.A. with a specialization in entrepreneurship and finance from Northeastern University and an M.D. from Jefferson Medical College, as well as a doctorate in biochemistry and molecular biology.- Douglas Kerr自2019年5月起担任我们的首席开发官。此前，克尔博士于2017年8月至2019年5月担任研究与开发首席科学官兼执行Vice President。在加入我们之前，Kerr博士于2015年10月至2017年8月担任生物制药公司Shire plc神经病学全球开发团队负责人兼Vice President。Kerr博士在普林斯顿大学（Princeton University）获得生物化学学士学位，并在东北大学（Northeastern University）获得工商管理硕士学位，专业是创业和金融，在杰斐逊医学院（Jefferson Medical College）获得医学博士学位，并获得生物化学和分子生物学博士学位。
- Douglas Kerr has served as our chief development officer since May 2019. Previously, Dr. Kerr served as our chief scientific officer and executive vice president of research and development from August 2017 to May 2019. Prior to joining us, Dr. Kerr served as global development team lead and vice president for neurology at Shire plc, a biopharmaceutical company, from October 2015 to August 2017. Dr. Kerr earned a B.A. degree in biochemistry from Princeton University and, an M.B.A. with a specialization in entrepreneurship and finance from Northeastern University and an M.D. from Jefferson Medical College, as well as a doctorate in biochemistry and molecular biology.
- Oxana Beskrovnaya
Oxana Beskrovnaya自2020年1月起担任我们的高级副总裁，研究主管。在加入我们之前，Beskrovnaya博士于2011年7月至2020年1月担任赛诺菲罕见疾病和神经科的肌肉骨骼和肾脏研究主管。Beskrovnaya博士是众多专利、特邀评论、社论、书籍章节和主要科学期刊原创研究文章的作者。Beskrovnaya博士在莫斯科遗传学研究所（Moscow Genetics Institute）获得遗传学博士学位，随后在爱荷华大学霍华德休斯医学研究所（Howard Hughes Medical Institute）接受神经肌肉疾病博士后奖学金培训。
Oxana Beskrovnaya has served as our Senior Vice President, Head of Research since January 2020. Prior to joining us, Dr. Beskrovnaya served as head of musculoskeletal and renal research in Sanofi’s rare disease and neurological unit from July 2011 to January 2020. Dr. Beskrovnaya is the author of numerous patents, invited reviews, editorials, book chapters and original research articles in major scientific journals. Dr. Beskrovnaya received her Ph.D. in genetics from Moscow Genetics Institute, followed by postdoctoral fellowship training in neuromuscular diseases at the Howard Hughes Medical Institute at the University of Iowa.- Oxana Beskrovnaya自2020年1月起担任我们的高级副总裁，研究主管。在加入我们之前，Beskrovnaya博士于2011年7月至2020年1月担任赛诺菲罕见疾病和神经科的肌肉骨骼和肾脏研究主管。Beskrovnaya博士是众多专利、特邀评论、社论、书籍章节和主要科学期刊原创研究文章的作者。Beskrovnaya博士在莫斯科遗传学研究所（Moscow Genetics Institute）获得遗传学博士学位，随后在爱荷华大学霍华德休斯医学研究所（Howard Hughes Medical Institute）接受神经肌肉疾病博士后奖学金培训。
- Oxana Beskrovnaya has served as our Senior Vice President, Head of Research since January 2020. Prior to joining us, Dr. Beskrovnaya served as head of musculoskeletal and renal research in Sanofi’s rare disease and neurological unit from July 2011 to January 2020. Dr. Beskrovnaya is the author of numerous patents, invited reviews, editorials, book chapters and original research articles in major scientific journals. Dr. Beskrovnaya received her Ph.D. in genetics from Moscow Genetics Institute, followed by postdoctoral fellowship training in neuromuscular diseases at the Howard Hughes Medical Institute at the University of Iowa.
- Johanna Friedl Naderer
Johanna Friedl Naderer，自2024年9月起担任Dyne Therapeutics, Inc.首席商务官。在加入Dyne Therapeutics, Inc.之前，Friedl-Naderer女士于2022年3月至2024年3月在传染病领域担任Vir Biotechnology公司执行副总裁兼首席运营官。从2019年11月至2022年1月，她担任渤健公司欧洲、加拿大和合作伙伴市场总裁，在渤健 20多年的任期内，她担任的职务越来越多，涉及广泛的职能，在推进获得用于治疗神经系统疾病（包括多发性硬化症、脊髓性肌萎缩症、肌萎缩侧索硬化症和阿尔茨海默病）的药物方面建立并领导团队。Friedl-Naderer女士还曾在多个董事会任职，包括欧洲制药工业与协会联合会。
Johanna Friedl Naderer,has served as Dyne Therapeutics, Inc. Chief Commercial Officer since September 2024. Prior to joining Dyne Therapeutics, Inc., Ms. Friedl-Naderer served as Executive Vice President and Chief Operating Officer of Vir Biotechnology, Inc. in the field of infectious disease from March 2022 to March 2024. As president Europe, Canada & Partner Markets for Biogen Inc. from November 2019 to January 2022,During her more than 20-year tenure at Biogen, she held positions of increasing responsibility across a wide range of functions, building and leading teams in advancing access to medicines for the treatment of neurological conditions, including multiple sclerosis, spinal muscular atrophy, amyotrophic lateral sclerosis and Alzheimer's disease. Ms. Friedl-Naderer has also served on several boards including the European Federation of Pharmaceutical Industries & Associations.- Johanna Friedl Naderer，自2024年9月起担任Dyne Therapeutics, Inc.首席商务官。在加入Dyne Therapeutics, Inc.之前，Friedl-Naderer女士于2022年3月至2024年3月在传染病领域担任Vir Biotechnology公司执行副总裁兼首席运营官。从2019年11月至2022年1月，她担任渤健公司欧洲、加拿大和合作伙伴市场总裁，在渤健 20多年的任期内，她担任的职务越来越多，涉及广泛的职能，在推进获得用于治疗神经系统疾病（包括多发性硬化症、脊髓性肌萎缩症、肌萎缩侧索硬化症和阿尔茨海默病）的药物方面建立并领导团队。Friedl-Naderer女士还曾在多个董事会任职，包括欧洲制药工业与协会联合会。
- Johanna Friedl Naderer,has served as Dyne Therapeutics, Inc. Chief Commercial Officer since September 2024. Prior to joining Dyne Therapeutics, Inc., Ms. Friedl-Naderer served as Executive Vice President and Chief Operating Officer of Vir Biotechnology, Inc. in the field of infectious disease from March 2022 to March 2024. As president Europe, Canada & Partner Markets for Biogen Inc. from November 2019 to January 2022,During her more than 20-year tenure at Biogen, she held positions of increasing responsibility across a wide range of functions, building and leading teams in advancing access to medicines for the treatment of neurological conditions, including multiple sclerosis, spinal muscular atrophy, amyotrophic lateral sclerosis and Alzheimer's disease. Ms. Friedl-Naderer has also served on several boards including the European Federation of Pharmaceutical Industries & Associations.
- John G. Cox
John G. Cox从2013年11月开始担任Repligen董事。Cox先生目前是Biogen Idec执行副总，负责医药运营&科技，这个职位他从2010年6月开始担任。Cox先生也担任Technical Operations高级副总，Global Manufacturing高级副总，Biogen Idec在北加州的Research Triangle Park的业务的生产负责和总经理，以及生产负责人。Cox先生在2003年加入Biogen Idec，作为生产科学负责人。在加入Biogen Idec之前，在2000年到2003年之间，Cox先生担任Diosynth许多高级运营岗位，在那他任职于科技转化，验证和纯化。在那之前，在1993年到2000年之间，Cox先生在Wyeth LLC关注相同的领域。Cox先生获得California State University的细胞生物学士学位和the University of Michigan的金融类工商管理研究生学位。
John G. Cox has served as a director of Repligen since November 2013. Mr. Cox is currently the CEO of Bioverativ Inc. Previously, he was the Executive Vice President of Pharmaceutical Operations & Technology at Biogen Inc., a position he held for six years. Mr. Cox has also served as Senior Vice President of Technical Operations, Senior Vice President of Global Manufacturing, Vice President of Manufacturing & General Manager of Biogen's operations in Research Triangle Park, North Carolina, and Director of Manufacturing. Mr. Cox joined Biogen in 2003 as Director of Manufacturing Sciences. Before joining Biogen from 2000 to 2003 Mr. Cox held a number of senior operational roles at Diosynth where he worked in technology transfer, validation and purification. Prior to that, Mr. Cox focused on the same areas at Wyeth LLC from 1993 to 2000. Mr. Cox received a B.S. in cell biology from California State University and an M.A. in Business Administration in Finance degree from the University of Michigan.- John G. Cox从2013年11月开始担任Repligen董事。Cox先生目前是Biogen Idec执行副总，负责医药运营&科技，这个职位他从2010年6月开始担任。Cox先生也担任Technical Operations高级副总，Global Manufacturing高级副总，Biogen Idec在北加州的Research Triangle Park的业务的生产负责和总经理，以及生产负责人。Cox先生在2003年加入Biogen Idec，作为生产科学负责人。在加入Biogen Idec之前，在2000年到2003年之间，Cox先生担任Diosynth许多高级运营岗位，在那他任职于科技转化，验证和纯化。在那之前，在1993年到2000年之间，Cox先生在Wyeth LLC关注相同的领域。Cox先生获得California State University的细胞生物学士学位和the University of Michigan的金融类工商管理研究生学位。
- John G. Cox has served as a director of Repligen since November 2013. Mr. Cox is currently the CEO of Bioverativ Inc. Previously, he was the Executive Vice President of Pharmaceutical Operations & Technology at Biogen Inc., a position he held for six years. Mr. Cox has also served as Senior Vice President of Technical Operations, Senior Vice President of Global Manufacturing, Vice President of Manufacturing & General Manager of Biogen's operations in Research Triangle Park, North Carolina, and Director of Manufacturing. Mr. Cox joined Biogen in 2003 as Director of Manufacturing Sciences. Before joining Biogen from 2000 to 2003 Mr. Cox held a number of senior operational roles at Diosynth where he worked in technology transfer, validation and purification. Prior to that, Mr. Cox focused on the same areas at Wyeth LLC from 1993 to 2000. Mr. Cox received a B.S. in cell biology from California State University and an M.A. in Business Administration in Finance degree from the University of Michigan.